The Company is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, the Company intends to focus our search on companies in the healthcare industry.
Company profile
Ticker
BLAC, BLACU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
845052822
BLAC stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Apr 24
10-K
2023 FY
Annual report
17 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Entry into a Material Definitive Agreement
11 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Feb 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
425
Business combination disclosure
16 Nov 23
Latest ownership filings
SC 13G
Bellevue Global Life Science Investors LLC
8 Feb 24
SC 13G/A
Space Summit Capital LLC
5 Feb 24
4
Kuk Hyoun Hwang
27 Mar 23
4
David Jin Yoo
27 Mar 23
4
Change in insider ownership
27 Mar 23
4
Kuk Hyoun Hwang
23 Feb 23
4
Change in insider ownership
23 Feb 23
4
STEVEN REED
16 Feb 23
4
In Chul Chung
16 Feb 23
4
Rad Roberts
16 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.96 k | 57.96 k | 57.96 k | 57.96 k | 57.96 k | |
Cash burn (monthly) | (no burn) | 5.55 k | 273.62 k | 159.72 k | 4.04 k | |
Cash used (since last report) | n/a | 40.34 k | 1.99 mm | 1.16 mm | 29.36 k | |
Cash remaining | n/a | 17.61 k | -1.93 mm | -1.10 mm | 28.60 k | |
Runway (months of cash) | n/a | 3.2 | -7.1 | -6.9 | 7.1 |
Institutional ownership, Q4 2023
7.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 3 |
Closed positions | 32 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.25 bn |
Total shares | 405.05 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Schechter Investment Advisors | 211.23 k | $2.22 bn |
Deltec Asset Management | 106.25 k | $1.12 bn |
Wealthspring Capital | 87.58 k | $919.58 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Mar 23 | David Jin Yoo | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 20,000 |
23 Mar 23 | David Jin Yoo | Warrant for Common Stock Common Stock | Grant | Acquire A | No | No | 11.5 | 20,000 | 230.00 k | 20,000 |
23 Mar 23 | Bellevue Global Life Science Investors | Common Stock | Other | Dispose J | No | No | 0 | 20,000 | 0.00 | 2,000,500 |
23 Mar 23 | Bellevue Global Life Science Investors | Warrant for Common Stock Common Stock | Other | Dispose J | No | No | 11.5 | 20,000 | 230.00 k | 370,000 |
23 Mar 23 | Kuk Hyoun Hwang | Common Stock | Other | Dispose J | Yes | No | 0 | 20,000 | 0.00 | 2,000,500 |
23 Mar 23 | Kuk Hyoun Hwang | Warrant for Common Stock Common Stock | Other | Dispose J | Yes | No | 11.5 | 20,000 | 230.00 k | 370,000 |
21 Feb 23 | Kuk Hyoun Hwang | Common Stock | Other | Dispose J | Yes | No | 0 | 4,500 | 0.00 | 2,020,500 |
21 Feb 23 | Kuk Hyoun Hwang | Common Stock | Other | Acquire J | Yes | No | 0 | 225,000 | 0.00 | 2,025,000 |
21 Feb 23 | Bellevue Global Life Science Investors | Common Stock | Other | Dispose J | No | No | 0 | 4,500 | 0.00 | 2,020,500 |
21 Feb 23 | Bellevue Global Life Science Investors | Common Stock | Other | Acquire J | No | No | 0 | 225,000 | 0.00 | 2,025,000 |